What Gestational Diabetes Actually Is
Gestational diabetes (GDM) is a type of high blood sugar that develops during pregnancy. It affects roughly 10 to 15 percent of pregnancies worldwide. It can cause complications for both the mother and baby — including large birth weight, early delivery, and a higher chance of type 2 diabetes later in life.
Right now, most women are only tested for GDM in the second trimester. Identifying risk earlier could give doctors and patients more time to make lifestyle changes that lower blood sugar and improve outcomes.
The Protein No One Expected
For years, lipoprotein(a) — often written as Lp(a) — has been studied mostly as a risk factor for heart disease. It is a type of cholesterol-carrying particle in the blood. High levels of Lp(a) are generally seen as bad news for the heart.
But here's the twist: this study found that low Lp(a) levels — not high ones — were linked to a greater risk of developing gestational diabetes.
How Lp(a) Might Be Involved
The exact reason for this connection is not yet fully understood. Think of Lp(a) as a vehicle that carries cholesterol through your blood. During pregnancy, the body's cholesterol and fat metabolism shifts dramatically. Researchers believe that low Lp(a) early in pregnancy may reflect a broader imbalance in fat and sugar processing — one that makes it harder for the body to regulate blood glucose later on.
It is also possible that Lp(a) plays a protective role in how the placenta functions or how the body handles insulin during pregnancy. More work is needed to pin down the exact mechanism.
The Study at a Glance
Researchers conducted a retrospective (looking back at past records) cohort study of 14,527 pregnant women seen between September 2021 and January 2024. They used a statistical technique called propensity score matching to create fair comparisons — pairing 922 women who developed GDM with 922 who did not, based on similar baseline characteristics.
All women had their Lp(a) levels measured within the first 20 weeks of pregnancy.
Women who later developed gestational diabetes had significantly lower Lp(a) levels in early pregnancy compared to those who did not develop GDM.
Specifically, women with Lp(a) below 50 mg/L were about 45% more likely to develop GDM compared to those with levels of 300 mg/L or higher. Women with levels between 50 and 300 mg/L were about 35% more likely. The association held up even after accounting for factors like maternal age and pre-pregnancy BMI.
That's Not the Full Story
This doesn't mean Lp(a) is ready to replace current GDM screening tools.
The finding is intriguing, but it raises as many questions as it answers. Lp(a) is not currently part of routine prenatal blood panels. And this study can only show that low Lp(a) is associated with GDM — it cannot prove that low Lp(a) directly causes it.
Why This Could Matter for Prenatal Care
If confirmed in larger studies, Lp(a) measured in early pregnancy could become one piece of a broader risk assessment tool. Doctors might use it alongside other factors — like BMI, family history, and age — to identify which patients need closer monitoring or early dietary counseling.
This could be especially useful in women who have no other obvious risk factors but still develop GDM, a group that current screening sometimes misses until late in pregnancy.
Right now, Lp(a) is not a standard prenatal test, and this research alone is not enough to change clinical practice. If you are pregnant or planning a pregnancy and have concerns about gestational diabetes risk, the most useful conversation to have is with your OB-GYN or midwife about your personal risk factors. Healthy diet, regular movement, and maintaining a healthy weight before and during pregnancy remain the most established ways to reduce GDM risk.
Where the Evidence Has Limits
This study looked back at existing medical records, which means it cannot fully control for all variables. It was also conducted at a single center in China, and Lp(a) levels vary significantly by ethnicity — so results may not apply equally to all populations. A prospective study — one that tracks women forward in time — would provide stronger evidence.
Researchers next need to test whether adding Lp(a) to first-trimester screening panels actually helps predict GDM in diverse populations and whether early identification leads to better outcomes. If prospective trials confirm the association, clinical guidelines could eventually be updated to include Lp(a) as part of early pregnancy risk stratification — giving more women a chance to act on their risk before complications develop.
